There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gamida Cell (GMDA – Research Report) and Neurosense Therapeutics Ltd. (NRSN – Research Report) with bullish sentiments.
Gamida Cell (GMDA)
Needham analyst Gil Blum maintained a Buy rating on Gamida Cell today and set a price target of $9.00. The company’s shares closed last Thursday at $1.78, close to its 52-week low of $1.47.
According to TipRanks.com, Blum has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $14.20, implying a 787.5% upside from current levels. In a report issued on September 19, JMP Securities also reiterated a Buy rating on the stock with a $17.00 price target.
See today’s best-performing stocks on TipRanks >>
Neurosense Therapeutics Ltd. (NRSN)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Neurosense Therapeutics Ltd., with a price target of $7.00. The company’s shares closed last Thursday at $1.74, close to its 52-week low of $1.23.
According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMDA:
- Pokemoto Enters South Carolina Market
- First Bank Announces Third Quarter 2022 Earnings Conference Call
- Stock Market Today: Nasdaq Leads Bearish Sentiment for Stocks
- Wacker Chemie AG (WKCMF) Gets a Buy from Stifel Nicolaus
- Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Roche Holding AG (OtherRHHVF)
